The role of mass spectrometry to implement protein biomarkers in clinical studies for precision medicine

Proteomics Interest Group Understanding cancer biology at a molecular level has dramatically changed therapeutic strategies in oncology and improved patient care. As drugs become more targeted with clearer mode of actions, it is important to implement robust biomarkers into drug development process to precisely identify the right patients for clinical trials, to deliver safer and more effective drugs, and to reduce overall developmental costs. While genetic biomarkers are widely used, implementing protein biomarkers remains challenging in part due to the lack of robust technologies fit for clinical laboratories. Recently, mass spectrometry (MS) has been increasingly applied to clinical studies to overcome major limitations of immunohistochemistry, which is the standard method of protein-based diagnostics. In this lecture, we will discuss how SRM-based protein assays improve clinical studies compared to immuno-assays, and future directions of the MS-based quantitative methodologies for clinical applications with a focus on the emerging DIA-based approach.For more information go tohttp://proteome.nih.govAir date: 5/2/2019 10:00:00 AM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video